Sulis Therapeutics ApS
CVR 44445832 · Private limited company (ApS) · Active · High risk
Sulis Therapeutics ApS is a Private limited company (ApS), founded on , based in København N. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 3.4% over the next 12 months, which is 2.4 times the average for Danish companies. 3 annual reports have been published. The latest annual report (31 Dec 2025) shows equity of DKK -939k and a net result of DKK -893k. CEO: Claus Elsborg Olesen.
Bankruptcy risk for Sulis Therapeutics ApS
2.4 × the average (1.41%) · higher risk than 88% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 44445832
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (2 years)
- Address
- Ole Maaløes Vej 3
2200 København N - Municipality
- København
- Industry
- Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik - Share capital
- DKK 100k
- Auditor
- EY Godkendt Revisionspartnerselskab
- Audit opted out
- No
Warning signs
| Annual reports filed late | 0 of 3 |
| Missing annual report | No |
| Negative equity | Yes |
| Equity ratio | -62.4% |
| Current ratio | 388% |
| Moves (last 2 years) | 0 |
| CEO changes in total | 0 |
| CEO's previous bankruptcies | 1 |
| Other companies at the address | 167 |
| Going-concern uncertainty | Yes |
Financials and key figures
| Financial year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Gross profit | DKK -866k | DKK -167k | DKK -2,013 |
| Net profit | DKK -893k | DKK -202k | DKK -4,540 |
| Equity | DKK -939k | DKK -46k | DKK 156k |
| Total assets | DKK 1.5m | DKK 533k | DKK 196k |
| Cash | DKK 1.2m | DKK 367k | – |
| Short-term debt | DKK 365k | DKK 33k | – |
| Avg. employees | 1 | 1 | – |
Latest annual report: Reporting class B · auditor's statement: Revisionspåtegning · EY Godkendt Revisionspartnerselskab.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2025 – 31 Dec 2025 | 153 | ||
| 1 Jan 2024 – 31 Dec 2024 | 147 | ||
| 21 Nov 2023 – 31 Dec 2023 | 129 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Claus Elsborg Olesen | Current | |
| Board | Martin Roelsgaard Jakobsen | Current | |
| Board | Claus Elsborg Olesen | Current | |
| Board | Sten Verland | Current | |
| Board | Sten Verland | ||
| Board | Morten Døssing | ||
| Board | Martin Roelsgaard Jakobsen | ||
| Board | Christian Schetter | ||
| Board | Natalie Rose Sacks | ||
| Board | Regina Hodits | ||
| Board | Claus Elsborg Olesen | ||
| Owner (50%) | CLAUS OLESEN HOLDING ApS | Current | |
| Owner (15%) | MR Jakobsen Holding ApS | Current | |
| Owner (25%) | Shinka Life Sciences AB | Current | |
| Owner (100%) | STIPE Therapeutics ApS | ||
| Owner (10%) | CLAUS OLESEN HOLDING ApS | ||
| Owner (20%) | Novo Holdings A/S | ||
| Owner (20%) | Sunstone Life Science Ventures Fund IV K/S | ||
| Owner (10%) | MR Jakobsen Holding ApS | ||
| Owner (20%) | Wellington Partners Life Sciences V GmbH & Co. KG | ||
| Auditor | EY Godkendt Revisionspartnerselskab | Current | |
| Founder | STIPE Therapeutics ApS | Current |
The CEOs' other companies
Claus Elsborg Olesen – 10 other companies, of which 1 bankrupt
- STIPE Therapeutics ApS Bankrupt 3 Feb 2026
- CLAUS OLESEN HOLDING ApS Active
- Ceoth ApS Active
- Initiator Pharma A/S Active
- Kariya Pharmaceuticals ApS Active
- MACOL SAILING ApS Opløst
- MATCH RACE CENTER ÅRHUS ApS Opløst
- NMD Pharma A/S Active
- PCOVERY ApS Opløst
- Synuca Therapeutics ApS Active
Address history (2 moves)
| Ole Maaløes Vej 3, 2200 København N | |
| c/o STipe Therapeutics ApS, Ole Maaløes Vej 3, 2200 København N | |
| c/o STipe Therapeutics ApS, Inge Lehmanns Gade 10, 8000 Aarhus C |
Former names
| Sulis Therapeutics ApS | – now |
| Selskabet af 21. november 2023 ApS | – |
Other companies at the same address
- 25-06-2019 ApS Bankrupt
- Ankrin Therapeutics ApS Bankrupt
- Avineuro ApS Bankrupt
- BIOREPELLER IVS Bankrupt
- Bainan Biotech ApS Bankrupt
- Broselid Holding IVS Bankrupt
- ChildTreat ApS Bankrupt
- Dencomm ApS Bankrupt
- IO BIOTECH ApS Bankrupt
- Invitreo Biosciences ApS Bankrupt
- Lab Hos Development ApS Bankrupt
- MGM BIO IVS Bankrupt
- Mind the Byte ApS Bankrupt
- PanCryos ApS Bankrupt
- Ressaissi Holding IVS Bankrupt
- SSIP 2023 ApS Bankrupt
- Spit Test Company ApS Bankrupt
- Sterisafe Holding A/S Bankrupt
- Sumondo ApS Bankrupt
- TychoBio IVS Bankrupt
- aiwell Nordic ApS Bankrupt
- 1stBiome ApS Active
- 3Sonic ApS Active
- 55 North General Partner I ApS Active
- 55 North Management ApS Active
Similar companies in København
- CARLSBERG A/S København V
- CuraVision ApS København V
- Launch Bioindustries ApS København Ø
- RheumaLogics ApS København Ø
- Vitibiotech ApS København N
- Pyovita ApS Hellerup
- ArcanaBio ApS København N
- OvartiX ApS København N
- Keystone Consulting ApS København SV
- KPL ApS København N
- Alveus Therapeutics ApS København K
- Cambiotics ApS København N
Questions and answers about Sulis Therapeutics ApS
Has Sulis Therapeutics ApS gone bankrupt?
No, Sulis Therapeutics ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of Sulis Therapeutics ApS?
Our model estimates a bankruptcy risk of 3.4% over the next 12 months (high risk), which is 2.4 times the average for Danish companies.
Who is the CEO of Sulis Therapeutics ApS?
Claus Elsborg Olesen is the CEO of Sulis Therapeutics ApS.
Who is the auditor of Sulis Therapeutics ApS?
Sulis Therapeutics ApS most recently used EY Godkendt Revisionspartnerselskab.
When was Sulis Therapeutics ApS founded?
Sulis Therapeutics ApS was founded on 21 November 2023.
What is the equity of Sulis Therapeutics ApS?
Equity was DKK -939k according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.